Literature DB >> 22912406

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.

Hozefa S Bandukwala1, John Gagnon, Susan Togher, Jason A Greenbaum, Edward D Lamperti, Nigel J Parr, Amy M H Molesworth, Nicholas Smithers, Kevin Lee, Jason Witherington, David F Tough, Rab K Prinjha, Bjoern Peters, Anjana Rao.   

Abstract

Bromodomain-containing proteins bind acetylated lysine residues on histone tails and are involved in the recruitment of additional factors that mediate histone modifications and enable transcription. A compound, I-BET-762, that inhibits binding of an acetylated histone peptide to proteins of the bromodomain and extra-terminal domain (BET) family, was previously shown to suppress the production of proinflammatory proteins by macrophages and block acute inflammation in mice. Here, we investigated the effect of short-term treatment with I-BET-762 on T-cell function. Treatment of naïve CD4(+) T cells with I-BET-762 during the first 2 d of differentiation had long-lasting effects on subsequent gene expression and cytokine production. Gene expression analysis revealed up-regulated expression of several antiinflammatory gene products, including IL-10, Lag3, and Egr2, and down-regulated expression of several proinflammatory cytokines including GM-CSF and IL-17. The short 2-d treatment with I-BET-762 inhibited the ability of antigen-specific T cells, differentiated under Th1 but not Th17 conditions in vitro, to induce pathogenesis in an adoptive transfer model of experimental autoimmune encephalomyelitis. The suppressive effects of I-BET-762 on T-cell mediated inflammation in vivo were accompanied by decreased recruitment of macrophages, consistent with decreased GM-CSF production by CNS-infiltrating T cells. These effects were mimicked by an inhibitor of c-myc function, implicating reduced expression of c-myc and GM-CSF as one avenue by which I-BET-762 suppresses the inflammatory functions of T cells. Our study demonstrates that inhibiting the functions of BET-family proteins during early T-cell differentiation causes long-lasting suppression of the proinflammatory functions of Th1 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22912406      PMCID: PMC3437860          DOI: 10.1073/pnas.1212264109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  NFATc1 regulates PD-1 expression upon T cell activation.

Authors:  Kenneth J Oestreich; Hyesuk Yoon; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex.

Authors:  J K Tong; C A Hassig; G R Schnitzler; R E Kingston; S L Schreiber
Journal:  Nature       Date:  1998-10-29       Impact factor: 49.962

3.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

Review 4.  Experimental autoimmune encephalomyelitis--achievements and prospective advances.

Authors:  Helena Batoulis; Mascha S Recks; Klaus Addicks; Stefanie Kuerten
Journal:  APMIS       Date:  2011-10-18       Impact factor: 3.205

Review 5.  Manipulation of the Th1/Th2 balance in autoimmune disease.

Authors:  L B Nicholson; V K Kuchroo
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

6.  Low molecular weight inhibitors of Myc-Max interaction and function.

Authors:  Xiaoying Yin; Christine Giap; John S Lazo; Edward V Prochownik
Journal:  Oncogene       Date:  2003-09-18       Impact factor: 9.867

7.  JMJD6 is a histone arginine demethylase.

Authors:  Bingsheng Chang; Yue Chen; Yingming Zhao; Richard K Bruick
Journal:  Science       Date:  2007-10-19       Impact factor: 47.728

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  Sequential expression of genes involved in human T lymphocyte growth and differentiation.

Authors:  M Krönke; W J Leonard; J M Depper; W C Greene
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  90 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

2.  Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.

Authors:  Beatriz Suarez-Alvarez; José Luis Morgado-Pascual; Sandra Rayego-Mateos; Ramon M Rodriguez; Raul Rodrigues-Diez; Pablo Cannata-Ortiz; Ana B Sanz; Jesus Egido; Pierre-Louis Tharaux; Alberto Ortiz; Carlos Lopez-Larrea; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

Review 3.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

Review 4.  Metabolic regulation of T cell differentiation and function.

Authors:  Benjamin V Park; Fan Pan
Journal:  Mol Immunol       Date:  2015-08-12       Impact factor: 4.407

5.  Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation.

Authors:  Ka Lung Cheung; Fan Zhang; Anbalagan Jaganathan; Rajal Sharma; Qiang Zhang; Tsuyoshi Konuma; Tong Shen; June-Yong Lee; Chunyan Ren; Chih-Hung Chen; Geming Lu; Matthew R Olson; Weijia Zhang; Mark H Kaplan; Dan R Littman; Martin J Walsh; Huabao Xiong; Lei Zeng; Ming-Ming Zhou
Journal:  Mol Cell       Date:  2017-03-03       Impact factor: 17.970

6.  BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.

Authors:  Kalung Cheung; Geming Lu; Rajal Sharma; Adam Vincek; Ruihua Zhang; Alexander N Plotnikov; Fan Zhang; Qiang Zhang; Ying Ju; Yuan Hu; Li Zhao; Xinye Han; Jamel Meslamani; Feihong Xu; Anbalagan Jaganathan; Tong Shen; Hongfa Zhu; Elena Rusinova; Lei Zeng; Jiachi Zhou; Jianjun Yang; Liang Peng; Michael Ohlmeyer; Martin J Walsh; David Y Zhang; Huabao Xiong; Ming-Ming Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 7.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

8.  I-BET151 selectively regulates IL-6 production.

Authors:  Elyse Barrett; Shaun Brothers; Claes Wahlestedt; Eléonore Beurel
Journal:  Biochim Biophys Acta       Date:  2014-05-22

9.  JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300-mediated acetylation of RORγt.

Authors:  Xiunan Wang; Yan Yang; Dandan Ren; Yuanyuan Xia; Wenguang He; Qingsi Wu; Junling Zhang; Miao Liu; Yinan Du; Cuiping Ren; Bin Li; Jijia Shen; Yuxia Zhang
Journal:  Br J Pharmacol       Date:  2020-03-23       Impact factor: 8.739

10.  EPIGENETIC MECHANISMS IN MULTIPLE SCLEROSIS.

Authors:  Mar Gacias; Patrizia Casaccia
Journal:  Rev Esp Escler Mult       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.